First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies-MedSci.cn

First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies

Ailawadhi, S; Chen, Z; Huang, B; Paulus, A; Collins, M; Fu, L; Li, MY; Ahmad, M; Men, LC; Wang, HB; Davids, M; Liang, E; Mekala, D; He, ZC; Lasica, M; Yannakou, C; Parrondo, R; Glass, L; Yang, DJ; Chanan-Khan, A; Zhai, YF

LEUKEMIA & LYMPHOMA, 2023; 64 (): S76

科室
- - 订阅+
  - 更多科室
工具
服务